Literature DB >> 434689

The use of thrombolytic agents: choice of patient, drug administration, laboratory monitoring.

V J Marder.   

Abstract

A proper choice of patient is critical in assuring both a satisfactory degree of lysis of the thrombus or embolus and a clinical course uncomplicated by serious hemorrhage. The best patients to treat are those who are seriously and acutely ill but without anatomic lesions that may bleed excessively. Thrombolytic agents can be administered by standard courses of therapy, and the monitoring of treatment with laboratory tests has been simplified and is concerned primarily with the documentation of a "lytic state."

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 434689     DOI: 10.7326/0003-4819-90-5-802

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  14 in total

1.  Why thrombolytic therapy.

Authors:  S Sherry
Journal:  West J Med       Date:  1981-02

2.  Selective low-dose streptokinase infusion in the treatment of acute transplant renal vein thrombosis.

Authors:  J M Robinson; C H Cockrell; J Tisnado; M C Beachley; M P Posner; T F Tracy
Journal:  Cardiovasc Intervent Radiol       Date:  1986       Impact factor: 2.740

3.  Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator.

Authors:  J Owen; K D Friedman; B A Grossman; C Wilkins; A D Berke; E R Powers
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

4.  Acute renal failure following repeated streptokinase therapy for pulmonary embolism.

Authors:  R A Pick; B C Joswig; A K Cheung; I M Cohen
Journal:  West J Med       Date:  1983-06

5.  Urokinase therapy of subclavian-axillary vein thrombosis.

Authors:  R Zimmermann; H Mörl; J Harenberg; P Gerhardt; H M Kuhn; P Wahl
Journal:  Klin Wochenschr       Date:  1981-08-03

Review 6.  Physiological balance of haemostasis and bleeding.

Authors:  V J Marder; C W Francis
Journal:  Drugs       Date:  1987       Impact factor: 9.546

7.  Summary of early clinical experience with anisoylated plasminogen streptokinase activator complex in the treatment of acute myocardial infarction.

Authors:  D Jackson
Journal:  Drugs       Date:  1987       Impact factor: 9.546

8.  A first-in-human phase I trial of locally delivered human plasmin for hemodialysis graft occlusion.

Authors:  R D Shlansky-Goldberg; A H Matsumoto; G A Baumbach; J B Siegel; R D Raabe; T P Murphy; C Deng; J Ray Dawkins; V J Marder
Journal:  J Thromb Haemost       Date:  2008-04-02       Impact factor: 5.824

9.  Venous gangrene of the upper extremity.

Authors:  B M Smith; G W Shield; D H Riddell; J D Snell
Journal:  Ann Surg       Date:  1985-04       Impact factor: 12.969

Review 10.  Adverse reactions to thrombolytic agents. Implications for coronary reperfusion following myocardial infarction.

Authors:  J Nazari; R Davison; K Kaplan; D Fintel
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.